What’s Happening at the NIH?
|
In a recent article published in The Atlantic that addresses the current situation at the NIH and its implications, Moores Director Diane Simeone, MD, describes how resultant pauses in funding can affect clinical trials for cancer patients. Learn More>>
|
Share Your AACR and ASCO 2025 Presentations
|
If you are presenting at the American Association for Cancer Research (AACR) and/or American Society of Clinical Oncology (ASCO) annual meeting for 2025, then please, using the link below, inform Moores administration, which will spread the word among the Moores community. Reach Out Now>>
|
A Message from UC San Diego Chancellor Pradeep K. Khosla
|
Moores recognizes the anxiety and uncertainty surrounding recent and proposed changes in federal research funding policies. Leadership at Moores and UC San Diego are engaged in addressing these changes by collaborating with peer institutions and advocating at the federal and state level to safeguard research efforts and minimize disruptions. Moores and UC San Diego remain dedicated to fostering groundbreaking research and supporting the community. For updates and opportunities to participate in advocacy efforts, visit the UC San Diego Federal Policy updates webpage.
A message from Chancellor Pradeep K. Khosla>>
|
|
|
Forging the Future of Cancer Research Through Education
|
Moores Members Joshua Demb, PhD, and Asona Lui, MD, PhD, demonstrate how the educational environment at Moores prepares and empowers early-career researchers in becoming faculty members and leaders in cancer research. Learn More>>
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
Curebound Grants for 2025
|
Budget: $250,000 for 1 year
|
Letter of Intent (LOI) Deadline: May 5, 2025
|
Application Deadline: July 29, 2025 for Selected Applicants Only
|
Budget: $500,000 for 2 years
|
LOI Deadline: May 5, 2025
|
Application Deadline: July 29, 2025 for Selected Applicants Only
|
Budget: $1,000,000 for 2–3 years
|
LOI Deadline: May 5, 2025
|
Application Deadline: July 29, 2025 for Selected Applicants Only
|
Budget: $250,000 for 1 year
|
LOI Deadline: May 5, 2025
|
Application Deadline: July 29, 2025 for Selected Applicants Only
|
Budget: $250,000 for 1 year
|
LOI Deadline: May 5, 2025
|
Application Deadline: July 29, 2025 for Selected Applicants Only
|
The Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP), Peer Reviewed Cancer Research Program (PRCRP) has released a pre-announcement for these anticipated funding opportunities:
|
-
Career Development Award—Fellow and Resident Option
- Career Development Award—Scholar Option
- Idea Award
- Impact Award—Partnering PI Option
- Patient Well-Being and Survivorship Award
- Clinical Trial Award
|
The DoD CDMRP Melanoma Research Program (MRP) has released a pre-announcement for these anticipated funding opportunities:
|
- Survivorship Research Award
- Focused Program Award—Rare Melanomas
- Melanoma Academy Leadership Award
- Idea Award
- Melanoma Academy Scholar Award
- Team Science Award
|
|
|
|
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
|
Silvio Gutkind, PhD (Cancer Biology and Signaling)
|
|
|
| Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO Living Guideline, Version 2024.3
|
Journal of Clinical Oncology
|
Lyudmila Bazhenova, MD (Solid Tumor Therapeutics)
|
|
|
| PSSR2: A user-friendly Python package for democratizing deep learning-based point-scanning super-resolution microscopy
|
Uri Manor, PhD (Cancer Biology and Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO)
|
TEAD-AST-101: A Phase Ia/Ib Dose Escalation, Dose Expansion Study of SW682 in Participants with Advanced Solid Tumors Enriched for Those with Hippo Pathway Mutations
PI: Sandip Patel, MD
NCT: NCT06251310
EAY191-A6: FOLFOX in Combination with Binimetinib as 2nd-Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A Combo-MATCH Treatment Trial
PI: Shumei Kato, MD
NCT: NCT05564403
CRB-601-01: A Phase I/II Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB601, a Monoclonal Antibody against Integrin v8, in Patients with Advanced Solid Tumors
PI: Shumei Kato, MD
NCT: NCT06603844
|
|
|
|
